A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies, Administered Alone or in Combination With Ruxolitinib, in Participants With CALR-mutant Myeloproliferative Neoplasms
Status: Recruiting
Location: See all (36) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential thrombocythemia (ET) and myelofibrosis (MF), and of DMR-001 in combination with ruxolitinib in participants with CALR-mutant MF.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and the protocol.
• Diagnosis/confirmation of ET or MF as defined in the protocol.
• Documented CALR exon-9 mutation.
• Willingness to undergo bone marrow biopsy and aspiration per the Schedule of Assessments.
Locations
United States
Alabama
Site US07
NOT_YET_RECRUITING
Birmingham
Arizona
Site US26
NOT_YET_RECRUITING
Gilbert
California
Site US11
NOT_YET_RECRUITING
Duarte
Site US25
NOT_YET_RECRUITING
Irvine
Florida
Site US04
NOT_YET_RECRUITING
Tampa
Georgia
Site US15
NOT_YET_RECRUITING
Atlanta
Kansas
Site US21
NOT_YET_RECRUITING
Kansas City
Massachusetts
Site US03
NOT_YET_RECRUITING
Boston
Site US12
NOT_YET_RECRUITING
Boston
Maryland
Site US18
NOT_YET_RECRUITING
Baltimore
Michigan
Site US06
NOT_YET_RECRUITING
Ann Arbor
Missouri
Site US08
NOT_YET_RECRUITING
St Louis
North Carolina
Site US14
NOT_YET_RECRUITING
Charlotte
Site US24
NOT_YET_RECRUITING
Durham
Site US13
NOT_YET_RECRUITING
Winston-salem
New York
Site US17
NOT_YET_RECRUITING
Babylon
Site US01
NOT_YET_RECRUITING
New York
Site US02
NOT_YET_RECRUITING
New York
Ohio
Site US05
NOT_YET_RECRUITING
Columbus
Oregon
Site US20
NOT_YET_RECRUITING
Eugene
Tennessee
Site US19
NOT_YET_RECRUITING
Nashville
Texas
Site US10
NOT_YET_RECRUITING
Houston
Utah
Site US16
NOT_YET_RECRUITING
Salt Lake City
Virginia
Site US23
NOT_YET_RECRUITING
Richmond
Washington
Site US22
NOT_YET_RECRUITING
Seattle
Other Locations
Australia
Site AU01
NOT_YET_RECRUITING
Adelaide
Site AU11
NOT_YET_RECRUITING
Brisbane
Site AU08
NOT_YET_RECRUITING
Liverpool
Site AU02
RECRUITING
Melbourne
Site AU03
RECRUITING
Melbourne
Site AU04
NOT_YET_RECRUITING
Melbourne
Site AU07
NOT_YET_RECRUITING
Newcastle
Site AU05
NOT_YET_RECRUITING
Perth
Site AU10
NOT_YET_RECRUITING
Sunshine Coast
Site AU06
NOT_YET_RECRUITING
Sydney
Site AU09
RECRUITING
Sydney
Contact Information
Primary
Damora Therapeutics Medical Monitor
ClinicalTrials@Damoratx.com
+1 782-281-9020
Time Frame
Start Date: 2026-09
Estimated Completion Date: 2030-06
Participants
Target number of participants: 250
Treatments
Experimental: Part 1: DMR-001 monotherapy dose escalation phase.
DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the protocol defined starting dose and dosing schedule to identify the maximum tolerated dose and/or recommended dose(s) for expansion.
Experimental: Part 2: DMR-001 monotherapy dose expansion phase.
DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the determined recommended dose(s) for expansion based on Part 1.
Experimental: Part 3: DMR-001 and ruxolitinib combination dose escalation followed by dose expansion.
DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the determined dose and regimen, but in combination with an oral tablet of ruxolitinib, a standard of care drug approved therapy for the treatment of MF.
Related Therapeutic Areas
Sponsors
Leads: Damora Therapeutics